By Ramsey Baghdadi
Does experience matter with a drug when making approval decisions for new indications in different disease areas? Yes, says FDA Office of Oncology Drug Products director Richard Pazdur.
Defining Cancer Drug Development Part II: A Discussion with FDA's Pazdur
FDA’s top oncology drug regulator says experience and history matter when making review decisions on supplemental indications for therapies already on the market.